147 related articles for article (PubMed ID: 38230679)
21. Combination of 7-
Chen Y; Li X; Shi L; Ma P; Wang W; Wu N; Gan Y; Han X; Huang S; Kang X; Liu S; Zhen Y
Aging (Albany NY); 2022 Sep; 14(17):7156-7169. PubMed ID: 36107024
[TBL] [Abstract][Full Text] [Related]
22. Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo.
Stein U; Walther W; Lemm M; Naundorf H; Fichtner I
Int J Cancer; 1997 Sep; 72(5):885-91. PubMed ID: 9311609
[TBL] [Abstract][Full Text] [Related]
23. Novel mechanisms of drug resistance in leukemia.
Ross DD
Leukemia; 2000 Mar; 14(3):467-73. PubMed ID: 10720143
[TBL] [Abstract][Full Text] [Related]
24. Reversal of chemoresistance with small interference RNA (siRNA) in etoposide resistant acute myeloid leukemia cells (HL-60).
Kachalaki S; Baradaran B; Majidi J; Yousefi M; Shanehbandi D; Mohammadinejad S; Mansoori B
Biomed Pharmacother; 2015 Oct; 75():100-4. PubMed ID: 26463638
[TBL] [Abstract][Full Text] [Related]
25. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
[TBL] [Abstract][Full Text] [Related]
26. Cancer Drug Resistance Reduction via Co-treatment with Oxaliplatin and Nitazoxanide: Targeting the ABC Transporters.
Hemmati-Dinarvand M; Mokhtari H; Alipourfard I; Beyrami Aghbash E; Kheirandish S; Khodadadian A; Seghatoleslam A
Curr Mol Med; 2023; 23(8):834-841. PubMed ID: 35996253
[TBL] [Abstract][Full Text] [Related]
27. Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells.
Quiney C; Billard C; Faussat AM; Salanoubat C; Kolb JP
Leuk Lymphoma; 2007 Aug; 48(8):1587-99. PubMed ID: 17701591
[TBL] [Abstract][Full Text] [Related]
28. [Multidrug resistance mechanisms in cell line HL-60/VCR].
Zhu XH; Li JY; Xia XM; Zhu MQ; Geng MJ; Chen L; Zhang JQ
Ai Zheng; 2002 Dec; 21(12):1310-3. PubMed ID: 12520737
[TBL] [Abstract][Full Text] [Related]
29. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
Grundy M; Seedhouse C; Russell NH; Pallis M
BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
[TBL] [Abstract][Full Text] [Related]
30. Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR).
Lee CH
Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):43-52. PubMed ID: 14754411
[TBL] [Abstract][Full Text] [Related]
31. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
[TBL] [Abstract][Full Text] [Related]
32. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
33. Update on drug transporter proteins in acute myeloid leukemia: Pathological implication and clinical setting.
Vasconcelos FC; de Souza PS; Hancio T; de Faria FCC; Maia RC
Crit Rev Oncol Hematol; 2021 Apr; 160():103281. PubMed ID: 33667660
[TBL] [Abstract][Full Text] [Related]
34. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines.
Nuessler V; Stötzer O; Gullis E; Pelka-Fleischer R; Pogrebniak A; Gieseler F; Wilmanns W
Leukemia; 1999 Nov; 13(11):1864-72. PubMed ID: 10557064
[TBL] [Abstract][Full Text] [Related]
35. [Mechanism of Apoptosis for Resveratrol-mediated Reversing the Drug-resistance of AML HL-60/ADR cells].
Guo YK; Shi M; Qin YL; Li YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):736-742. PubMed ID: 28641627
[TBL] [Abstract][Full Text] [Related]
36. Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia.
Marcelletti JF; Sikic BI; Cripe LD; Paietta E
Cytometry B Clin Cytom; 2019 Jan; 96(1):57-66. PubMed ID: 30334334
[TBL] [Abstract][Full Text] [Related]
37. Overcoming Multidrug Resistance: Flavonoid and Terpenoid Nitrogen-Containing Derivatives as ABC Transporter Modulators.
M F Gonçalves B; S P Cardoso D; U Ferreira MJ
Molecules; 2020 Jul; 25(15):. PubMed ID: 32722234
[TBL] [Abstract][Full Text] [Related]
38. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
39. P-glycoprotein and multidrug resistance-associated protein-1 expression in acute myeloid leukemia: Biological and prognosis implications.
da Silveira Júnior LS; Soares VL; Jardim da Silva AS; Gil EA; Pereira de Araújo MDG; Merces Gonçalves CA; Paiva AS; Moura de Oliveira TM; Oliveira GHM; Kramer Cavacanti E Silva DG; de Araújo Moura Lemos TM; Moretti Rebecchi IM; de Farias Sales VS; Luchessi AD; Cavalcanti Júnior GB
Int J Lab Hematol; 2020 Oct; 42(5):594-603. PubMed ID: 32452631
[TBL] [Abstract][Full Text] [Related]
40. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia.
den Boer ML; Pieters R; Kazemier KM; Rottier MM; Zwaan CM; Kaspers GJ; Janka-Schaub G; Henze G; Creutzig U; Scheper RJ; Veerman AJ
Blood; 1998 Mar; 91(6):2092-8. PubMed ID: 9490695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
